



Paras Healthcare Limited

Two Decades of Excellence

8 Hospitals (2 upcoming)
*across **6** States and **1** Union Territory*

Targeting **3,011 Beds** by 2028

Investor Presentation

Q2 & H1 FY27

Our Hospitals : Gurugram, Patna, Darbhanga, Panchkula, Ranchi, Udaipur, Srinagar and Kanpur
Upcoming Hospitals : Gurugram-Golf Course Extension and Ludhiana

Disclaimer

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Paras Healthcare Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness



Q2 & H1FY27

Operational & Financial Highlights

Q2 FY27 Vs Q2 FY 26: Momentum Across Revenue and Profits


Revenue	**INR 510.9 Crs** vs INR 416.1 Crs	**+22.8%** YoY Growth	
Op. EBITDA ***(Excl other income)***	**INR 120.2 Crs** vs INR 81.7 Crs	**+47.0%** YoY Growth	***23.5% | 19.6%*** ***Op. EBITDA Margins*** **growth of 390 bps**
Reported EBITDA ***(incl other income)***	**INR 126.6 Crs** vs INR 88.8 Crs	**+42.5%** YoY Growth	***24.5% | 21.0%*** ***Reported EBITDA Margins*** **growth of 350 bps**
PAT	**INR 40.4 Crs** vs INR 12.4 Crs	**3.3x** YoY Growth	***7.8% | 2.9%*** ***PAT Margins*** **growth of 490 bps**

H1 FY27 vs H1 FY26 : Growth Compounding into Profitability

Revenue	**INR 981.2 Crs** vs INR 784.5 Crs	**+25.1%** YoY Growth	
Op. EBITDA ***(Excl other income)***	**INR 225.2 Crs** vs INR 142.2 Crs	**+58.4%** YoY Growth	***23.0% | 18.1 %*** ***Op. EBITDA Margins*** **growth of 480 bps**
Reported EBITDA ***(incl other income)***	**INR 240.1 Crs** vs INR 155.2 Crs	**+54.7%** YoY Growth	***24.1% | 19.5 %*** ***Reported EBITDA Margins*** **growth of 465 bps**
PAT	**INR 90.0 Crs** vs INR 11.4 Crs	**7.9x** YoY Growth	***9.0%*** PAT Margins vs **1.4%** in H1 FY26, **growth of 760 bps**

Operating Leverage in Action


Revenue from Operations (Rs. in Crs)



22.8%
YoY Revenue Growth
Q2FY27 vs Q2FY26

25.1%
YoY Revenue Growth
H1FY27 vs H1FY26

Operating EBITDA & Margin %



47.0%
YoY EBITDA Growth
Q2FY27 vs Q2FY26

58.4%
YoY EBITDA Growth
H1FY27 vs H1FY26

Our Hospital Cohorts : FY26

Mature (>7 years) – 1,076 Beds



Gurugram



Patna



Darbhanga



Panchkula

FY26 Revenue	**₹1,179 Cr**
Op. EBITDA Margin	**~26%**
Occupancy	**73.2%**

Stable and growing occupancy levels, strong clinical reputation and consistent margin expansion

Emerging (4–7 years) – 500 Beds



Ranchi



Udaipur

FY26 Revenue	**₹283 Cr**
Op. EBITDA Margin	**~15%**
Occupancy	**57.8%**

Shown improving occupancy and margin expansion as their scale of operations builds

New (<4 years) – 635 Beds



Srinagar



Kanpur

FY26 Revenue	**₹144 Cr**
Op. EBITDA Margin	**NM**
Occupancy	**33.8%**

Op. EBITDA improved by ₹51.7 Cr(1). Expected to follow a similar growth trajectory through occupancy improvement, addition of specialties and op. leverage.

Note: (1) From FY25 to FY26.


Q2 FY27: Newer hospitals ramp up continues


Mature Hospitals (> 7 years)


Emerging Hospitals (4 to 7 years)

New Hospitals (< 4 years)


Revenue from Operations (*Rs. in Crs*)









Operating EBITDA & Margin % (*Rs. in Crs*)







Note: Cohort Operating EBITDA is at hospital level, before corporate overheads, so cohorts do not add up to consolidated Operating EBITDA.


Bed Occupancy Rate (%) *Operating EBITDA Margin (%)*

H1 FY27: Newer hospitals moving to "Emerging"

Mature Hospitals (> 7 years)

Emerging Hospitals (4 to 7 years)

New Hospitals (< 4 years)



Note: Cohort Operating EBITDA is at hospital level, before corporate overheads, so cohorts do not add up to consolidated Operating EBITDA.

Bed Occupancy Rate (%) *Operating EBITDA Margin (%)*

Key Financial Ratios

Reported EBITDA Margin

24.1%

+465 bps vs H1 FY26

H1 FY26	FY26
19.5%	**20.6%**

Operating EBITDA Margin[2]

23.0%

+480 bps vs H1 FY26

H1 FY26	FY26
18.1%	**19.5%**

PAT Margin

9.0%

+760 bps vs H1 FY26

H1 FY26	FY26
1.4%	**2.7%**

Capital Employed

1,984.6 Cr

+21.9% vs H1 FY26

H1 FY26	FY26
1,628.4	**1,784.4**

Return on Equity (ROE)[1]

20.4%

+1,700 bps vs H1 FY26

H1 FY26	FY26
3.5%	**13.0%**

ROCE[1]

8.4%

+300 bps vs H1 FY26

H1 FY26	FY26
5.4%	**10.8%**

Adjusted ROCE[1]

10.7%


+400 bps vs H1 FY26

H1 FY26	FY26
6.7%	**13.6%**


[1] H1 FY27 and H1 FY26 ROE, ROCE and Adjusted ROCE are for six months and not annualised
[2] Operating EBITDA margin is EBITDA excluding other income as a percentage of revenue from operations.

Key Operating KPIs


Bed Capacity




ARPOB (Rs in '000)




Occupied Bed Days & Occupancy %




IP Volumes ('000)



OP Consultations ('000)



ALOS (in days)




Specialty And Payor Mix

Specialty Mix

CONGOR

H1 FY'26: 75%

H1 FY'27: 74%




Payor Mix

Self-Pay + Insurance

H1 FY'26: 69%

H1 FY'27 : 56%



Note: CONGOR – Cardiac sciences, Oncology, Neurosciences, Gastro Sciences, Orthopedics & Sports Injury, Renal Sciences.

20 Years of Compassionate Care



LISTED on 28 Oct 2026

2 Years OF COMPASSIONATE CARE

LEGACY



Recognized

CRISIL

BBB+ → A–

CRISIL upgraded the long-term rating by one notch

UPGRADED

Great Place To Work® Certified AUG 2026-AUG 2027 INDIA ™

92%

of employees say new joiners are made to feel welcome

CERTIFIED

Listed on NSE & BSE on 28 Oct 2026 · Times Now: #3 among multi-specialty groups of hospitals · CRISIL long-term rating upgraded to A– from BBB+ · Great Place To Work® Certified, Aug 2026–Aug 2027 (source: 2026 Trust Index® Survey)

Consolidated Profit & Loss Statement

Particulars (₹ Cr)	Q2FY27	Q2FY26	YoY	H1FY27	H1FY26	YoY	FY26
Revenue from Operations	**510.9**	**416.1**	**+22.8%**	**981.2**	**784.5**	**+25.1%**	**1,606.0**
Other Income	6.5	7.1		14.9	13.0		22.8
Total Income	**517.3**	**423.2**	**+22.2%**	**996.1**	**797.5**	**+24.9%**	**1,628.8**
COGS	123.3	114.2		238.4	216.4		430.2
Employee Cost	57.6	46.6		113.9	86.3		181.6
Doctor Cost	122.1	102.9		232.8	197.8		394.1
Other Expenses	87.8	70.7		170.9	141.8		287.3
EBITDA	**126.6**	**88.8**	**+42.5%**	**240.1**	**155.2**	**+54.7%**	**335.6**
EBITDA Margin	**24.5%**	**21.0%**	**+350 bps**	**24.1%**	**19.5%**	**+465 bps**	**20.6%**
Depreciation	38.7	34.3		73.8	66.9		143.6
Finance Cost	33.8	34.7		64.0	62.6		116.0
Profit before Tax	**54.2**	**19.8**	**+173.5%**	**102.3**	**25.7**	**+298.7%**	**76.0**
Tax	13.9	7.4		12.3	14.3		32.2
PAT	**40.4**	**12.4**	**+225.7%**	**90.0**	**11.4**	**+692.2%**	**43.8**
PAT Margin %	**7.8%**	**2.9%**	**+490 bps**	**9.0%**	**1.4%**	**+760 bps**	**2.7%**

Summary Consolidated Balance Sheet

Particulars (₹ Cr)	Sep-26	Mar-26
Cash & Cash Equivalents(1)	305.9	302.7
Inventories	39.4	31.9
Trade Receivable	517.9	349.6
Property, Plant and Equipment & Capital Work-in-Progress	703.5	702.3
Right-of-Use Assets	521.4	531.1
Goodwill	4.6	4.6
Other Assets(2)	223.0	149.0
Total Assets	**2,315.8**	**2,071.1**
Total Equity(3)	486.1	394.9
Borrowings(4)	979.0	854.1
Lease Liabilities(4)	541.7	539.8
Trade payable	247.2	208.1
Other Liabilities(5)	61.7	74.2
Total Liabilities & Equity	**2,315.8**	**2,071.1**

Note: (1) Includes bank balances other than cash & cash equivalents; (2) Includes other intangible assets, other financial assets (current as well as non-current), tax assets (net) (current as well as non-current) and other current and non-current assets; (3) Includes equity share capital and other equity; (4) Includes current as well as non-current portions, (5) Includes other financial liabilities, other current liabilities, other financial liabilities (current as well as non-current) provisions (current as well as non-current), and deferred tax liabilities (net).

Pro Forma Debt Position post use of IPO Proceeds

Particulars (₹ Cr)	As on 30th Sep 2026	Use of IPO Proceeds	Post-IPO (Pro forma)
Long-term borrowings	476.5	(375.0)	101.5
Short-term borrowings	502.5	–	502.5
Gross Debt	**979.0**	**(375.0)**	**604.0**
Cash & Cash Equivalents and bank deposits	360.0	101.0*	461.0
Net Debt	**619.0**	**(476.0)**	**143.0**
Total Equity	**486.1**	**476.0**	**962.1**
Gross Debt / Equity	**2.01x**		**0.63x**
Net Debt / Equity	**1.27x**		**0.15x**

*Net of IPO expenses (estimated)



About Paras Healthcare

High-Acuity Hospital Platform in North India : FY26

8
Hospitals
+2 upcoming · 5 States & 1 UT

2,211
Beds
to grow to **~3,011 by 2028**

₹1,606 Cr
Revenue from Operations
FY26

₹47,398
ARPOB
FY26

2.9 days
ALOS
FY26

75%
CONGOR share
FY26

62%
Occupancy
338,321 occupied bed days · FY26

1,011
Doctors
Experienced team, with 1,665 nurses

₹43.8 Cr
PAT
FY26

Vision

To provide affordable, accessible and quality healthcare services in North India and serve our patients with compassion

Strong North & East India Footprint, Significant Opportunity for Growth

Strategic Presence across High-Demand Catchments


Gurugram 1
***2006* | Beds: 300**

Panchkula
***2018* | Beds: 284**

Patna
***2013* | Beds: 392**

Udaipur
***2019* | Beds: 200**

Darbhanga
***2016* | Beds: 100**



Srinagar
***2023* | Beds: 200**

Kanpur
***2024* | Beds: 435**

Ranchi
***2019* | Beds: 300**

Ludhiana
***2028* | Beds : ~500**
Upcoming

Gurugram 2
***2027* | Beds : ~300**
Upcoming

North India healthcare Opportunity*

CAGR 10–12%
North Industry growth (FY26 to 30)

INR 3.6–3.8 tn FY30
Industry size (North India)

Low bed density per 10k population **(14 – 15 beds)** vs. South India, which is at 29 to 30 beds

Headroom for Beds
Bed shortfall in North India of **~424,714**

~60% of India's population lives in North & East India

Represents a large and underserved healthcare market

*Source: UIDAI, Crisil Intelligence.

From 200-bed hospital in 2006 to 3000+ beds by 2028

First corporate hospitals
in Gurugram (2006) and Patna (2013)[1]

2017 · Investment
INR 260 Cr primary
Commelina (Creador affiliate)

2025 · Investment **INR 80 Cr primary**
360 ONE & Axis AIF
2026 · Initial Public Offer
Offer size – INR 1,450 Cr

300 beds
2006
Gurugram
NABH in 2009

392 beds
2013
Patna
- Bihar's first NABH hospital
- First bone marrow transplant, 2017

100 beds
2016
Darbhanga

284 beds
2018
Panchkula
First hospital with AERB-licensed radiotherapy center in Panchkula

500 beds
2019
Ranchi: 300
Udaipur: 200[3]
Jharkhand and Rajasthan

200 beds
2023
Srinagar
Largest corporate super-specialty private hospital in J&K in terms of bed capacity


435 beds
2024
Kanpur
One of the largest private tertiary care hospitals in Kanpur by bed capacity


300 beds
2027
Gurugram II
Upcoming


500 beds
2028
Ludhiana
Upcoming





















Note: Numbers of beds in the timeline represent capacity beds (current capacity beds for Patna and Panchkula, while the others are for the end of FY26). (1) Among our listed peers; (2) Started with 200 beds capacity; (3) Ranchi upgraded to 300 beds in FY 2023 and Udaipur started with 200 beds in 2019.

Leading Underserved Markets of North India Through an Asset-Light Model

4 Mature Hospitals (>7 years) – 1,076 Beds



Gurugram (Owned)

Since 2006

First corporate hospital entrant in Gurugram

300 beds — NABH accredited



Patna (Revenue share + partial fixed rent)

Since 2013

NABH accredited in 2016**, 1st in Bihar**

392 beds — NABH accredited



Darbhanga (Revenue Share)

Since 2016

Tertiary care hub in **Mithilanchal**

100 beds — NABH accredited



Panchkula (Revenue share + partial fixed rent)

Since 2018

First hospital with **AERB-licensed radiotherapy center** in **Panchkula**

284 beds — NABH accredited

2 Emerging Hospitals (4–7 years) – 500 Beds



Udaipur (Owned)

Since 2019

3rd hospital in Udaipur to receive **NABH accreditation**

200 beds — NABH accredited



Ranchi (Revenue share + partial fixed rent)

Since 2019

Operated under PPP Model

300 beds — NABH accredited

2 New Hospitals (<4 years) – 635 Beds



Srinagar (Fixed rent)

Since 2023

Largest corporate super-specialty private hospital in J&K in terms of bed capacity

200 beds — NABH accredited



Kanpur (Fixed Rent)


Since 2024

One of the **largest private tertiary care hospitals** in Kanpur **by bed capacity**

435 beds

CLINICAL EXCELLENCE

Three Padma Shri awardees lead a clinical team backed by advanced technology



Dr. (Prof.) VS Mehta

Chairman Emeritus - Neurosurgery

Padma Shri Awardee



Dr. MV Padma Srivastava

Chairperson – Neurology

Padma Shri Awardee



Dr. (Prof.) Alka Kriplani

Chairperson – Obstetrics and Gynaecology

Padma Shri Awardee



Dr. John Mukhopadhyay

Director & Chief Consultant - Orthopedics

CME Dronacharya Awardee




Dr. Ahmad Abdul Hai

Director – General & Laparoscopic Surgery

Stephenson Gold Medalist in Surgery

Specialist Leaders Anchoring High-Acuity Care Delivery



PET Scan



Linear Accelerator



Robotic Arm



Surgical Robot



MRI

Best-in-Class Clinical Technology

- Dainik Bhaskar Award for Leading Multi-Specialty Hospital in (2025)
- 'One of the Best Healthcare Brands' by ET Edge and Times Group (2024)
- IHW Gold Award for Patient-Centric National Hospital (2025)
- #4 in Multi-Specialty Group of Hospitals in Times Network India Health Summit (2025)

Delivering High-Quality Clinical Care through Renowned Clinicians, Supported with Modern Equipment

LEADERSHIP

Doctor-led, professionally managed, independently governed



Dr. Dharminder Nagar, *Managing Director*

Harvard Business School
BITS Pilani, University of Mysore
Co-Chair FICCI Health Service

Recognition:

- ***Healthcare Personality of the Year*** *award at the 16th Healthcare Excellence Awards 2024 organized by FICCI*
- ***Global Health Leader*** *award at the IHW Global Leaders Awards, Dubai*
- ***Best Healthcare Entrepreneur of the Year*** *award at the 11th MT India Healthcare Awards, 2021*
- ***Healthcare Icon of the Year*** *award at the HealthNXT, 2018*

Experienced Senior Management Team



Dr. Kapil Garg
Director, Strategy & Growth, Business Intelligence
- Apollo
- Fortis
- Columbia Asia



Dilip Bidani
Group CFO
- IIMA, ICAI
- MobiKwik
- Max Hospitals
- Dr. Lal Path



Vineet Aggarwal
Group COO
- BE (CS &IT)
- Agilus Diagnostics
- Indus tower



Balkishan Sharma
Group CHRO & Bus. Transformn. Officer
- IIMA[1]
- Max Hospitals



Dr. Sonia Verma
Group Head, Projects Central Buying Unit & Services
- Manipal Academy
- BITS Pilani



Rahul Kumar
Company Secretary & Compliance Officer
- LLB, ICSI
- Fujifilm India
- Morepen laboratories

Backed by Renowned Board



Saurabh Sood
Chairman and Non-Executive Director
President & MD – GATX India



Dr. Kapil Garg
Whole Time Director



Kabir Thakur
Non-Executive Director (Nominee of Commelina Ltd)



Upendra Prasad Singh
Independent Director
Ex- IAS & IIT Kanpur



Nakul Anand
Independent Director
Ex-ITC Limited



Usha Rajeev
Independent Director
Ex-Partner PwC[2]

Marquee Investors to Navigate the Company towards Rapid Growth

Commelina[3]	360 ONE	Axis New Opportunities AIF

Note: (1) Max Healthcare Leadership Development Programme; (2) Price Waterhouse & Affiliate Firms; (3) An affiliate of Creador, a global private equity firm.

Listing on Indian Stock Exchanges – Beginning of a New Journey



Term	Detail
Offer size	**INR 1,450 Cr**
Fresh issue	INR 500 Cr
Offer for sale	INR 950 Cr (Promoter INR 300 Cr; Commelina Ltd INR 650Cr)
Use of proceeds:	INR 375 Cr - Term debt repayment INR 125 Cr - General corporate purpose
Listed On:	*NSE and BSE – 28th October 2026*

- Marquee global investors, including ADIA, BlackRock, Eastspring Investments, Government Pension Fund Global* and Natixis Investment Managers, participated as anchor investors
- Leading domestic institutional investors, including SBI MF, HDFC MF, ICICI Prudential MF, Kotak MF, WhiteOak, Edelweiss MF, ICICI Pru Life Insurance and 360 One participated in the anchor book

* Norges Bank Investment Management



What sets Paras Apart

Strengths & Growth Strategies

The Paras Edge:
Scale, Specialty, Efficiency, Excellence

One of the Largest Healthcare Providers in North India, Bihar and Jharkhand with a First-Mover Advantage

Our **first-mover advantage** drives **strong brand recognition** in **complex care services** across key urban centres, including **Gurugram, Patna, Panchkula, Srinagar and Kanpur**

Strong Focus on Tertiary and Quaternary Care with High Contribution from CONGOR Specialties

Tertiary and quaternary care platform with **~74.7% of FY26 revenue** coming from **CONGOR specialties**, reflecting **deep specialty-led capabilities** across high-acuity care areas

Capital-Efficient and Flexible Operating Model with Disciplined Expansion

A carefully calibrated mix of **owned, leased, revenue-sharing and public-private partnership** models allows us to **lower upfront capital intensity**, drive **faster market entry** in identified white spaces, and support **long-term operational scalability**

Delivering High-Quality Clinical Care through Renowned Clinicians, Supported with Modern Equipment

Advanced clinical platform with **559 ICU beds**, served by **renowned clinicians** and equipped with **LINACs, surgical robots and PET/CT scanners** to ensure **state-of-the-art clinical care**

Doctor-Led Professional Management Team with Proven Execution Capabilities

Founder-led healthcare platform with a track record of **commissioning and scaling hospitals** over more than two decades, home to **3 Padma Shri awardee doctors**, and supported by a **seasoned board**, **reputed institutional shareholders** and a **robust governance framework**

Robust IT Architecture Differentiates Our Service Delivery

Paras Health - IT Ecosystem Map


Clinical Core | Patient Digital | Finance & Ops | Communication | Analytics & Compliance

Patient Engagement & Digital

- **iOS App** — Appointments & Reports
- **Android App** — Appointments & Reports
- **CRM** — Patient Journey & Retention
- **AI Chat + Agent** — 24x7 Booking, Queries & FAQ
- **Website** — OPD Booking & Info Portal
- **Online Pay** — UPI, Card & Wallet Payments

Communication & Collaboration

- **WhatsApp** — Patient Alerts & Report Delivery
- **O365+ Icewarp** — Staff email & calendar
- **Service Mgmt.** — IT helpdesk & SLA tracking



Finance & Enterprise Operations

- **ERP** — Finance, stores & procurement
- **Asset Mgmt.** — Equipment AMC & Depreciation
- **Bank Integration** — Auto reconcile receipts & pay
- **Supplier/Dr. Contracts** — Vendor SLAs & Consultant Pay

Analytics & Compliance

- **Power BI** — Clinical, Financial & Ops Dashboards
- **Compliance Tool** — Contracts & Audit Readiness

Roadmap for Sustained, Profitable Growth

1	2	3	4	5
Scale Newer Hospitals	**Expand North India network**	**High-End Clinical programs**	**Attract and Retain Qualified and Experienced Clinicians**	**Improve Operational Efficiencies and Patient Experience**
• Ramp-up occupancy at Ranchi, Udaipur, Srinagar, Kanpur • **Attract and retain senior skilled clinicians** • Add **multi-specialty services** • Operationalize **additional beds** • **Increase empanelment**	• Scale-up capacity in core markets (**Gurgaon)** • Enter North Indian cities with unmet demand **(Ludhiana**) • Add fresh beds in existing cluster (**Panchkula)** on company owned land	• Bone marrow, liver & kidney **transplants** • **Robotics** at our centres • Extend **radiation oncology** to Srinagar and scale it at Ranchi / Udaipur	• Attract **senior** clinicians • Provide access to **advanced clinical equipment**, high-complexity case mix; • Create talent pipeline - academic programmes (DNB)	• Optimize **Specialty** and **payor** mix, **standardize formulary** • Improve bed occupancy • **Leverage digital investments** - EHR, BI dashboards, AI-assisted clinical tools, Insurance pre-authorization automation. Revenue cycle management



Annexures

Historical Consolidated Profit & Loss Statement

Particulars	H1FY27	FY26	FY25
Revenue from Operations	**981.2**	**1,606.0**	**1,294.1**
Consumption	238.4	430.2	336.8
Gross Profit	**742.8**	**1,175.7**	**957.2**
Gross Profit Margin	**75.7%**	**73.2%**	**74.0%**
Employee Cost	113.9	181.6	173.8
Doctor Cost	232.8	394.1	358.9
Other Expenses	170.9	287.3	288.2
Operating EBITDA	**225.2**	**312.7**	**136.3**
Operating EBITDA Margin	**23.0%**	**19.5%**	**10.5%**
Other Income	14.9	22.8	20.1
Depreciation	73.8	143.6	115.6
EBIT	**166.3**	**192.0**	**40.9**
EBIT Margin	**17.0%**	**12.0%**	**3.2%**
Finance Cost	64.0	116.0	90.9
Profit before Tax	**102.3**	**76.0**	**(50.0)**
Profit before Tax Margin	**10.3%**	**4.7%**	**-3.8%**
Tax	12.3	32.2	7.9
PAT	**90.0**	**43.8**	**(58.0)**
PAT Margin %	**9.0%**	**2.7%**	**-4.4%**
EPS	**8.92**	**4.34**	**–**

Historical Consolidated Balance Sheet

ASSETS	Sept-26	Mar-26	Mar-25
Non-current assets			
Property, plant and equipment	651.4	673.5	645.6
Capital work-in-progress	52.2	28.7	37.8
Other intangible assets	1.3	1.4	1.8
Right of use Assets	521.4	531.1	521.4
Financial assets			
Other financial assets	77.4	24.8	32.4
Other non-current assets	63.3	36.7	53.8
Sub-total - Non-Current Assets	**1,366.9**	**1,296.2**	**1,292.7**
Current assets			
Inventories	39.4	31.9	26.3
Financial assets			
Trade receivables	517.9	349.6	234.6
Cash and cash equivalents	44.5	47.2	37.2
Bank balances other than Cash and Cash equivalents	261.4	255.5	168.3
Other financial assets	59.6	44.0	45.6
Other current assets	26.1	11.7	5.8
Current tax assets	–	35.0	–
Sub-total - Current Assets	**948.9**	**774.9**	**517.7**
TOTAL - ASSETS	**2,315.8**	**2,071.1**	**1,810.5**

EQUITY AND LIABILITIES	Sept-26	Mar-26	Mar-25
Equity			
Equity Share capital	10.1	10.1	9.8
Other equity	476.0	384.8	270.7
Sub-total - Shareholders' funds	**486.1**	**394.9**	**280.5**
LIABILITIES			
Non-current liabilities			
Financial liabilities			
Borrowings	476.5	454.2	436.4
Lease Liabilities	505.4	492.9	461.9
Other non-current liabilities	11.9	10.7	12.2
Sub-total - Non-current liabilities	**993.8**	**957.8**	**910.5**
Current liabilities			
Financial liabilities			
Borrowings	502.5	399.9	291.5
Trade payables	247.2	208.1	190.5
Other financial liabilities	26.4	45.5	75.2
Other current liabilities	19.5	15.1	16.2
Provisions	3.9	2.9	3.7
Lease Liabilities	36.3	46.9	42.3
Sub-total - Current liabilities	**835.8**	**718.4**	**619.4**
TOTAL - EQUITY AND LIABILITIES	**2,315.8**	**2,071.1**	**1,810.5**

Thank You !

Paras Healthcare Limited

CIN: U85110HR1987PLC035823

Mr. Dilip Bidani / Mr. Sidharth Aggarwal

Email ID : Dilip.Bidani@parashealth.com

Email ID : Sidharth.Aggarwal@parashealth.com

Strategic Growth Advisors Private Limited (SGA)

CIN: U74140MH2010PTC204285

Mr. Sagar Shroff / Mr. Ayush Haria

sagar.shroff@sgapl.net / ayush.haria@sgapl.net

+91 98205 19303 / +91 98204 62966